Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03493802 · ClinicalTrials.gov registry record
Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 18
- Enrollment target
NCT03493802: Completed study, sponsored by Mayo Clinic.
NCT03493802 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03493802 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients with autosomal dominant polycystic kidney disease (ADPKD) present with abnormal endothelial function, increased levels of NOX4 activity and mitochondrial abnormalities, contributing to oxidative stress from early stages that correlate with disease severity.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2020-01-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03493802
The ClinicalTrials.gov registry entry for NCT03493802 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03493802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03493802 about?
NCT03493802 is a clinical study titled "Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD". The purpose of this study is to determine whether patients with autosomal dominant polycystic kidney disease (ADPKD) present with abnormal endothelial function, increased levels of NOX4 activity and mitochondrial abnormalities, contributing to oxidative stress from early stages that correlate with d...
What is the current status of trial NCT03493802?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2017-11-01. Estimated completion is 2020-01-17.
Who is sponsoring clinical trial NCT03493802?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.